AspenBio's AppyScore appendicitis test could face further delays
This article was originally published in Clinica
Executive Summary
A supplemental clinical trial designed to secure US market clearance of AspenBio Pharma's appendicitis blood test AppyScore could be delayed after the company added two new alternative endpoints.